Dynavax Technologies Corporation announced that Heather Rowe has been appointed vice president of investor relations and corporate communications. In this role, Ms. Rowe will be responsible for communicating Dynavax’s business objectives and accomplishments to all key stakeholders, including shareholders, the investment community, media and employees. Ms. Rowe brings to Dynavax more than 16 years of strategic communications experience, with 13 years of dedicated investor relations experience. Previously, Ms. Rowe was senior director of investor relations and corporate communications at Five Prime Therapeutics. Prior to that, she was director of investor relations at KYTHERA Biopharmaceuticals (acquired by Allergan). She previously held various investor relations and communications roles with increasing responsibility at AeroVironment, Allos Therapeutics (acquired by Spectrum Pharmaceuticals), Janus Capital Group and Myogen (acquired by Gilead Sciences). Ms. Rowe holds an M.A. in Mass Communications/Public Relations from Texas Tech University and a B.A. in Communication Studies, with minors in Marketing and Journalism from New Mexico State University. She is an active member of the National Investor Relations Institute (NIRI) and has served on the board of directors of the NIRI Rocky Mountain Chapter and the NIRI Los Angeles Chapter.